

# The Journey to AI Precision Diagnostics and the Impact on Patient Outcomes

by Mariano de Socarraz

CEO



# CORE PLUS


SERVICIOS CLINICOS Y PATOLOGICOS

- High complexity, CLIA certified laboratory
  - Anatomic Pathology
  - Cytopathology
  - Molecular
  - Clinical
- Established in 1996
- Located in Carolina & Ponce
- Island-wide services





- Healthcare IT Solutions
  - Consulting
  - Support
  - Development
  - Business Intelligence
- Established in 2014
- Healthcare IT Solutions
- Located in Carolina



# Industry Challenges

**40%**  
≥ 63 y/o



**2021**

Expected  
retirement apex




**>5700**

Professional  
shortage





**Positivity rate on the rise**

In **42%** between 2007 – 2017



Dynamic, image-based environment that enables the acquisition, management and interpretation of pathology information generated from a digitized glass slide.

# Digital Pathology




# The Results are In!

	Area Under the Curve	SPEC	SENS	# SLIDES
  SERVICIOS CLINICOS Y PATOLOGICOS	<b>0.994</b>	<b>96.9%</b>	<b>96.5%</b>	<b>1,019</b>
  Médecins pathologistes indépendants	0.99	97%	99%	1,142
  LIFE CHANGING MEDICINE	0.99	98.5%	97%%	1,627
 	0.99	96%	98%	3,466


# CASE 1

- 66 y/o male
- Elevated PSA
- Family Hx of Prostate Cancer




# CASE 1

- 66 y/o male
- Elevated PSA
- Family Hx of Prostate Cancer
- Dx = Prostate Adenocarcinoma Grade Group 2




## CASE 2

- 51 y/o male
- Slightly Elevated PSA



# CASE 2


- 51 y/o male
- Slightly Elevated PSA



## CASE 2


- 51 y/o male
- Slightly Elevated PSA
- Dx = Microfocus of Prostate Adenocarcinoma Grade Group 1

Measurement  
**0.3mm**




# CASE 2

- 51 y/o male
- Slightly Elevated PSA
- Dx = Microfocus of Prostate Adenocarcinoma Grade Group 1




Measurement  
**0.3mm**



IBEX

# 27% shorter diagnosis time with AI compared to a microscope!

## AVERAGE DIAGNOSIS TIME



Efficiency % was calculated as a ratio of GP to MIC diagnosis time

**MIC** – diagnosis by pathologist using the microscope

**GP** – diagnosis by pathologist using Galen Prostate

## EFFICIENCY GAINS IN STUDY TEST

Diagnosis	# Cases	Time (GP vs. MIC)
<b>Benign</b>	34	-32%
<b>Cancer</b>	85	-25%


- Diagnosis time was 27% shorter
- Efficiency gains were slightly higher for benign cases than for cancer cases

# The Power of AI in Pathology



**Automate** labor-intensive or mundane processes

- Increase **efficiency** and **repeatability**
  - Count mitoses
  - Segment glands
  - Characterize nuclei shape



**Augment** pathologist


- Improve **precision** and **productivity**
  - Find tumor in image
  - Predict one imaging modality or stain from another



**Innovate** to learn concepts beyond human capabilities


- Discover **new insights** and **drive impact**
  - Distinguish classes too complex for human experts
  - Infer molecular biomarkers from H&E
  - Predict patient outcome

# Computer-Extracted Features



**AI to Predict Breast Cancer Grade, ER status, Histologic and intrinsic subtypes**


**75 – 85% accuracy predicting ER status, RNA-based molecular subtype and risk of recurrence score.**





# Conclusion

# AI-Assisted Diagnosis by Pathologist



% of Revised Reports per AI

5.0%

Pathologist A

% of Revised Reports per AI


0.5%

Pathologist B

% of Revised Reports per AI

2.1%

Pathologist C




# AI-Assisted Diagnosis

Benign -> Adenocarcinoma	21
Benign -> ASAP	23
G6 -> G7	7

**2.3%**  
**Total**

Revised Reports





PUERTO RICO  
**Health & Insurance**  
CONFERENCE 2021

**Thank You!**